candesartan cilexetil has been researched along with Ventricular Dysfunction, Left in 9 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The initial dosage of candesartan was 4 mg/d; the dosage was increased to 16 mg/d if the drug was tolerated." | 6.69 | Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. ( Bart, BA; Califf, RM; Ertl, G; Granger, CB; Held, P; Kuch, J; Maggioni, AP; McMurray, J; Michelson, EL; Ohlin, G; Pfeffer, MA; Rouleau, JL; Sellers, MA; Sparapani, R; Stevenson, LW; Swedberg, K; Young, J; Yusuf, S, 2000) |
| " The aim of this study was to assess: (1) longitudinal change in circulating cardiovascular biomarkers, (2) the effect of metoprolol succinate and candesartan cilexetil on the biomarker response, and (3) the associations between on-treatment changes in biomarker concentrations and subsequent left ventricular dysfunction in patients with early breast cancer receiving anthracyclines." | 5.24 | Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study. ( Geisler, J; Gravdehaug, B; Gulati, G; Hagve, TA; Heck, SL; Hoffmann, P; Norseth, J; Omland, T; Ree, AH; Røsjø, H; Steine, K, 2017) |
| " The initial dosage of candesartan was 4 mg/d; the dosage was increased to 16 mg/d if the drug was tolerated." | 2.69 | Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. ( Bart, BA; Califf, RM; Ertl, G; Granger, CB; Held, P; Kuch, J; Maggioni, AP; McMurray, J; Michelson, EL; Ohlin, G; Pfeffer, MA; Rouleau, JL; Sellers, MA; Sparapani, R; Stevenson, LW; Swedberg, K; Young, J; Yusuf, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gulati, G | 1 |
| Heck, SL | 1 |
| Røsjø, H | 1 |
| Ree, AH | 1 |
| Hoffmann, P | 1 |
| Hagve, TA | 1 |
| Norseth, J | 1 |
| Gravdehaug, B | 1 |
| Steine, K | 1 |
| Geisler, J | 1 |
| Omland, T | 1 |
| Yamamoto, K | 2 |
| Mano, T | 2 |
| Yoshida, J | 2 |
| Sakata, Y | 2 |
| Nishikawa, N | 2 |
| Nishio, M | 1 |
| Ohtani, T | 1 |
| Hori, M | 2 |
| Miwa, T | 2 |
| Masuyama, T | 2 |
| Yamazaki, T | 1 |
| Shiojima, I | 1 |
| Komuro, I | 1 |
| Nagai, R | 1 |
| Yazaki, Y | 1 |
| Murakami, M | 1 |
| Inada, Y | 1 |
| Tazawa, S | 1 |
| Nakao, K | 1 |
| Komatsu, H | 1 |
| Hanatani, A | 1 |
| Yoshiyama, M | 1 |
| Takeuchi, K | 1 |
| Kim, S | 1 |
| Nakayama, K | 1 |
| Omura, T | 1 |
| Iwao, H | 1 |
| Yoshikawa, J | 1 |
| Granger, CB | 1 |
| Ertl, G | 1 |
| Kuch, J | 1 |
| Maggioni, AP | 1 |
| McMurray, J | 1 |
| Rouleau, JL | 1 |
| Stevenson, LW | 1 |
| Swedberg, K | 1 |
| Young, J | 1 |
| Yusuf, S | 2 |
| Califf, RM | 1 |
| Bart, BA | 1 |
| Held, P | 1 |
| Michelson, EL | 1 |
| Sellers, MA | 1 |
| Ohlin, G | 1 |
| Sparapani, R | 1 |
| Pfeffer, MA | 1 |
| Kobayashi, N | 1 |
| Nishikimi, T | 1 |
| Horinaka, S | 1 |
| Ishimitsu, T | 1 |
| Matsuoka, H | 1 |
| Tsuyuki, RT | 1 |
| McKelvie, RS | 1 |
| Arnold, JM | 1 |
| Barretto, AC | 1 |
| Carvalho, AC | 1 |
| Isaac, DL | 1 |
| Kitching, AD | 1 |
| Piegas, LS | 1 |
| Teo, KK | 1 |
| Sugawara, M | 1 |
| Yamaguchi, Y | 1 |
| Ookawara, T | 1 |
| Suzuki, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, 2x2 Factorial, Double Blind Trial of Candesartan and Metoprolol[NCT01434134] | Phase 2 | 130 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan cilexetil and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Involvement of the renin-angiotensin system in the development of left ventricular hypertrophy and dysfunction.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Calcium-Trans | 1994 |
3 trials available for candesartan cilexetil and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antibiotics, | 2017 |
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2000 |
Acute precipitants of congestive heart failure exacerbations.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dise | 2001 |
5 other studies available for candesartan cilexetil and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2005 |
Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventric
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardio | 1997 |
Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Benzi | 1998 |
Effects of TCV-116 on expression of NOS and adrenomedullin in failing heart of Dahl salt-sensitive rats.
Topics: Adrenomedullin; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Disea | 2001 |
Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart.
Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; | 2002 |